Deal of the Day — limited-time pharmacy picks!
Afadel 40mg Tablet

Afadel 40mg Tablet

Prescription requiredRx Required

Salt Composition: Afatinib

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

▼

10 Tablet in Bottle

About The Product

Lung Cancer, monotherapy

Afadel 40mg Tablet contains afatinib dimaleate as an active ingredient. It is used for the treatment of non-small cell lung cancer (NSCLC) whose tumors have abnormal epidermal growth factor receptor (EGFR) genes, and patients with metastatic, squamous NSCLC progressing after platinum-based chemotherapy.

Uses

Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor mutations
Metastatic non-small cell lung cancer progressing after platinum-based chemotherapy

Benefits

\

Side Effects

  • Undesired symptoms or responses vary from person to person as the human body reacts differently to the Afadel 40mg Tablet, but they typically resolve naturally within a few days as the body adjusts to the medicine, requiring no medical attention.
  • In case these symptoms don't go away and you face severe side effects, then immediately consult your doctor or medical team.
  • Some of the common side effects of the Afadel 40mg Tablet are: Fatigue Headache, Increased glucose level in blood Fever Imsomnia (diffficulty in sleeping)
  • High blood pressure Rash Indigestion Nausea diarrhea or constipation Tremors Loss of appetite Low blood count kidney damage

How To Use

  • Afadel 40mg Tablet should not be chewed, opened, or crushed; it must be swallowed to increase the effectiveness of the drug.
  • It is an oral medication that is taken once a day, at the same time each day, before food.
  • One should wait for at least 3 hours before taking Afadel 40mg Tablet.

How It Works

Afadel 40mg Tablet helps the cancer cells stop their growth. It inhibits the ErbB family of proteins, which includes EGFR (also known as the epidermal growth factor receptor, or ErbB1, ErbB2, ErbB3, and ErbB4) and HER2.

Growth and proliferation of cancer cells can be stopped or slowed the growth of cancer. Changes in the proteins can alter the cell division and multiplication of cancer cells.

Safety Advice

Alcohol
Excessive alcohol consumption can decrease the immunity of the individual and weaken the liver function. However, moderate levels of alcohol do not interfere with the working of the Afadel 40 mg Tablet, as per the research
Pregnancy
The Afadel 40mg Tablet should be injected after consulting the doctor; during pregnancy, it is not suggested to take it routinely. Afadel 40mg Tablet can be injected in case of severe, life-threatening conditions. However, it may harm the unborn.
Breast Feeding
The Afadel 40 mg Tablet is considered unsafe to be taken while breastfeeding, as there is a chance that it may pass to the developing baby through the breast milk of the mother. It is generally considered unsafe, and there is no clear evidence found in the clinical data on how it harms the baby.
Driving
Driving after taking the Afadel 40 mg Tablet affects or interferes with driving ability or disturbs while operating machinery. With fever or dizziness, neurological effects can be seen after taking the capsule; avoid driving until you feel better.
Kidney
The Afadel 40 mg Tablet is considered unsafe for people with kidney problems. It can damage the kidneys. Tacrolimus, present in the capsule, is nephrotoxic.
Liver
The Afadel 40 mg Tablet is generally considered unsafe for people with mild to moderate liver disease. Although regular monitoring of the enzyme is required. The dose should be adjusted; take it with caution.

FAQs

Afadel 40mg causes a decrease in fertility in both men and women.

Reference

Barron, F., de la Torre-Vallejo, M., Luna-Palencia, R. L., Cardona, A.

F., & Arrieta, O. (2025).

The safety of afatinib for the treatment of non-small cell lung cancer. Expert Opinion on Drug Safety, 15(11), 1563-1572.

Batra, U., Sharma, M., Jain, P., Narayan, S., Jain, A., Soni, S., & Nathany, S. (2024).

Indian experience of Afatinib for EGFR mutation-positive advanced lung adenocarcinoma: a real-world retrospective study. Indian Journal of Cancer, 61(4), 671-675.

Igawa, S., Ono, T., Kasajima, M., Kusuhara, S., Otani, S., Fukui, T.,& Naoki, K. (2020).

Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer. Investigational New Drugs, 38(6), 1906-1914.

Wu, Y. L., Zhou, C., Hu, C.

P., Feng, J., Lu, S., Huang, Y., & Geater, S. L.

(2024). Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

The lancet oncology, 15(2), 213-222. Zhang, L., Luo, Y., Chen, J., Cheng, T., Yang, H., Pan, C., & Jiang, Z.

(2021). Efficacy and Safety of Afatinib in the Treatment of Advanced Non‐Small‐Cell Lung Cancer with EGFR Mutations: A Meta‐Analysis of Real‐World Evidence.

Journal of Oncology, 2021(1), 8736288.

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026